Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Phibro Animal Health (PAHC) Long-Term Debt Repayments (2016 - 2026)

Phibro Animal Health has reported Long-Term Debt Repayments over the past 13 years, most recently at $70.0 million for Q4 2025.

  • For Q4 2025, Long-Term Debt Repayments fell 64.29% year-over-year to $70.0 million; the TTM value through Dec 2025 reached $289.0 million, down 53.24%, while the annual FY2025 figure was $621.0 million, 157.68% up from the prior year.
  • Long-Term Debt Repayments for Q4 2025 was $70.0 million at Phibro Animal Health, up from $58.0 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $264.0 million in Q3 2024 and troughed at $23.0 million in Q1 2023.
  • A 5-year average of $91.5 million and a median of $65.5 million in 2021 define the central range for Long-Term Debt Repayments.
  • Biggest five-year swings in Long-Term Debt Repayments: surged 913.46% in 2021 and later crashed 78.03% in 2025.
  • Year by year, Long-Term Debt Repayments stood at $80.0 million in 2021, then soared by 52.5% to $122.0 million in 2022, then tumbled by 63.11% to $45.0 million in 2023, then soared by 335.56% to $196.0 million in 2024, then plummeted by 64.29% to $70.0 million in 2025.
  • Business Quant data shows Long-Term Debt Repayments for PAHC at $70.0 million in Q4 2025, $58.0 million in Q3 2025, and $58.0 million in Q2 2025.